Brofaromine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Brofaromine.svg | |
| Brofaromine
| |
| Systematic (IUPAC) name | |
| 4-(7-bromo-5-methoxy-1-benzofuran-2-yl)piperidine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C14H16BrNO2 |
| Mol. mass | 310.186 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 98% |
| Metabolism | ? |
| Half life | 9 to 14 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Brofaromine is a reversible inhibitor of monoamine oxidase A primarily useful in the treat ment of depression and anxiety. It is not commercially available and is not being actively researched, possibly due to a lack of financial interest.[1]
Pharmacology
Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.
References
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |
| ||||
